Press release
Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking Clinical Advancements by 5+ Global Leaders - DelveInsight | Featuring Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis Pipeline 2025, DelveInsight
DelveInsight's "Primary Axillary Hyperhidrosis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Primary Axillary Hyperhidrosis Therapeutics Market and the breakthroughs shaping its future trajectory.
Explore the Cutting-Edge Landscape of Primary Axillary Hyperhidrosis Drug Development @ https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Primary Axillary Hyperhidrosis Pipeline Report
DelveInsight's Primary Axillary Hyperhidrosis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Primary Axillary Hyperhidrosis treatment.
In June 2024, the U.S. Food and Drug Administration (FDA) approved SofdraTM (sofpironium bromide) topical gel, 12.45% for the treatment of primary axillary hyperhidrosis-a condition characterized by excessive underarm sweating. This approval marks the first new chemical entity sanctioned in the U.S. specifically for this condition .
Key Primary Axillary Hyperhidrosis companies such as Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG Arzneimittel, and others are evaluating new drugs for Primary Axillary Hyperhidrosis to improve the treatment landscape.
Promising Primary Axillary Hyperhidrosis pipeline therapies in various stages of development include Sofpironium Bromide, DMT-410, and others.
Primary Axillary Hyperhidrosis Overview:
Primary hyperhidrosis is an uncommon condition marked by excessive sweating in specific areas such as the palms, soles, groin, or beneath the breasts. One subtype, Primary Axillary Hyperhidrosis, involves excessive underarm sweating. While the exact cause is unclear, it is believed to result from heightened cholinergic sympathetic activity stimulating the sweat glands in the underarm region. This condition affects both men and women equally and typically begins during childhood or adolescence.
Download the Primary Axillary Hyperhidrosis sample report to know in detail about the Primary Axillary Hyperhidrosis treatment market @ https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Primary Axillary Hyperhidrosis Pipeline Analysis
The Primary Axillary Hyperhidrosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Primary Axillary Hyperhidrosis Market.
Categorizes Primary Axillary Hyperhidrosis therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Primary Axillary Hyperhidrosis drugs under development based on:
Stage of development
Primary Axillary Hyperhidrosis Route of administration
Target receptor
Monotherapy vs. combination therapy
Primary Axillary Hyperhidrosis Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Primary Axillary Hyperhidrosis Licensing agreements
Funding and investment activities supporting future Primary Axillary Hyperhidrosis market advancement.
Unlock key insights into emerging Primary Axillary Hyperhidrosis therapies and market strategies here: https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Primary Axillary Hyperhidrosis Emerging Drugs
Sofpironium Bromide - Brickell Biotech Inc.
Brickell Biotech's flagship investigational therapy, Sofpironium Bromide, is a topically applied small molecule designed to treat Primary Axillary Hyperhidrosis. It functions as a retro-metabolically engineered anticholinergic that selectively targets M3 acetylcholine receptors, potentially reducing sweat gland activity.
DMT-410 - Dermata Therapeutics LLC
Dermata Therapeutics is developing DMT-410, a combination treatment that pairs DMT-310 with botulinum toxin, for managing axillary hyperhidrosis. The drug combination has delivered encouraging outcomes in Phase I clinical trials.
Primary Axillary Hyperhidrosis Pipeline Therapeutic Assessment
Primary Axillary Hyperhidrosis Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Primary Axillary Hyperhidrosis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Primary Axillary Hyperhidrosis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Primary Axillary Hyperhidrosis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Primary Axillary Hyperhidrosis therapies and key Primary Axillary Hyperhidrosis companies: https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Primary Axillary Hyperhidrosis Current Treatment Patterns
4. Primary Axillary Hyperhidrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Axillary Hyperhidrosis Late-Stage Products (Phase-III)
7. Primary Axillary Hyperhidrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Axillary Hyperhidrosis Discontinued Products
13. Primary Axillary Hyperhidrosis Product Profiles
14. Primary Axillary Hyperhidrosis Key Companies
15. Primary Axillary Hyperhidrosis Key Products
16. Dormant and Discontinued Products
17. Primary Axillary Hyperhidrosis Unmet Needs
18. Primary Axillary Hyperhidrosis Future Perspectives
19. Primary Axillary Hyperhidrosis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Primary Axillary Hyperhidrosis pipeline reports offerings: https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking Clinical Advancements by 5+ Global Leaders - DelveInsight | Featuring Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG Arzneimittel here
News-ID: 4052352 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
